Cargando…

A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%

PURPOSE: To compare the effect of topical prednisolone acetate 1% (PA) used after routine cataract surgery to the effect of difluprednate 0.05% (DFBA) used for the same indication on intraocular pressure (IOP). METHODS: An electronic query was created to gather information from all cataract surgerie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusne, Yael, Kang, Paul, Fintelmann, Robert E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125796/ https://www.ncbi.nlm.nih.gov/pubmed/27920493 http://dx.doi.org/10.2147/OPTH.S121849

Ejemplares similares

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana, Claudia, et al.
Publicado: (2020)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

Therapeutic Efficacy of Difluprednate 0.05% Versus Prednisolone Acetate 1% in Controlling Inflammation and Macular Oedema Following Phacoemulsification: An Optical Coherence Tomography-Based Study
por: Panda, Bijnya B, et al.
Publicado: (2021)

Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis
por: KhalafAllah, Mahmoud Tawfik, et al.
Publicado: (2019)

Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010)

Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study
por: Wilson, M E, et al.
Publicado: (2016)

Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate
por: Mercado-Sesma, Arieh, et al.
Publicado: (2017)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Quantz, Katelin, et al.
Publicado: (2021)

Prednisolone-acetate: Increased intraocular pressure: case report
Publicado: (2022)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

A Primary Dead-Weight Tester for Pressures (0.05–1.0) MPa
por: Jain, Kamlesh, et al.
Publicado: (2003)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery
por: Lee, Jang Hoon, et al.
Publicado: (2016)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

Electrochemical properties of La(0.5)Sr(0.5)Fe(0.95)Mo(0.05)O(3−δ) as cathode materials for IT-SOEC
por: Hou, Yunting, et al.
Publicado: (2021)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Electronic, electrical and thermoelectric properties of Ba(0.95)Ca(0.05)Ti(0.95)Y(0.05)O(2.975) compound: Experimental study and DFT-mBJ calculation
por: Saidi, A., et al.
Publicado: (2023)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Topical difluprednate for the treatment of Harada’s disease
por: Onishi, Spencer M, et al.
Publicado: (2015)

Efficacy of 0.05% cyclosporine A on the lipid layer and meibomian glands after cataract surgery: A randomized, double-masked study
por: Kang, Min Seung, et al.
Publicado: (2021)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

p < 0.05, < 0.01, < 0.001, < 0.0001, < 0.00001, < 0.000001, or < 0.0000001 …
por: Zhu, Weimo
Publicado: (2016)

On the challenges of drawing conclusions from p-values just below 0.05
por: Lakens, Daniël
Publicado: (2015)

Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%
por: Bettencourt, Miriam S
Publicado: (2016)

The earth is flat (p > 0.05): significance thresholds and the crisis of unreplicable research
por: Amrhein, Valentin, et al.
Publicado: (2017)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi, Takanori, et al.
Publicado: (2017)

Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
por: Bhargava, Rahul, et al.
Publicado: (2019)

Comparing the antiplaque efficacy of 0.5% Camellia sinensis extract, 0.05% sodium fluoride, and 0.2% chlorhexidine gluconate mouthwash in children
por: Hambire, Chaitali U., et al.
Publicado: (2015)

Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese
por: Wu, Macy M. S., et al.
Publicado: (2014)

Difluprednate for the prevention of ocular inflammation postsurgery: an update
por: Donnenfeld, Eric D
Publicado: (2011)

The role of difluprednate ophthalmic emulsion in clinical practice
por: Jamal, Karim N, et al.
Publicado: (2009)

Analogous Anti-Ferroelectricity in Y(2)O(3)-Coated (Pb(0.92)Sr(0.05)La(0.02))(Zr(0.7)Sn(0.25)Ti(0.05))O(3) Ceramics and Their Energy-Storage Performance
por: Fang, Bijun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aup51jfcn82vjsmvg006ae10pb